14 trends tracked about this subject — the full history, oldest to newest below.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk’s once‑dominant GLP‑1 weight‑loss line now faces a fierce showdown with Eli Lilly, sparking questions about Europe’s biotech edge.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pharmaceutical giant Novo Nordisk faces a significant setback following the failure of a late-stage cardiovascular drug trial.
Novo Nordisk faces a significant setback in expanding beyond obesity as a key phase 3 trial delivers disappointing results.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
FDA’s new peptide panel sparks regulatory debate as biotech giants Lilly and Novo eye the next health wave.
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising data from a phase 1/2 human clinical trial.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.